Laboratorios Rubió, a renowned healthcare provider specializing in therapeutic solutions for low-prevalence diseases, has acquired a significant 30% stake in the biotech company Biosfer Teslab. This spin-off from the University Rovira i Virgili (URV) and the Institut d’Investigació Sanitària Pere Virgili (IISPV), is pioneering a novel diagnostic test for cardiovascular risk prediction in Europe.
Committed to propelling biotech innovations, Rubió is investing over half a million euros in R&D. This investment will pave the way for the final phase of product development and its subsequent commercialization in the healthcare sector.
The diagnostic test, a major product from this biotech company, is an advanced lipoprotein test with the following distinctive features:
As part of this strategic partnership in the biotech sphere, Laboratorios Rubió will gain:
The diagnostic test, set to revolutionize healthcare and particularly cardiovascular risk assessment, is expected to hit the market in 2016.
Laboratorios Rubió’s acquisition of stake in the biotech company Biosfer Teslab signifies its unwavering dedication to advancing healthcare through innovative solutions, particularly for low-prevalence diseases.
This strategic collaboration will play a pivotal role in enhancing early detection and prevention of cardiovascular diseases, thereby fortifying Laboratorios Rubió’s position as a frontrunner in healthcare and therapeutic solutions.